NAT10 (N-acetyltransferase 10) is an evolutionarily conserved enzyme belonging to the GCN5-related N-acetyltransferase (GNAT) family. It catalyzes the transfer of acetyl groups to RNA, particularly mediating N4-acetylcytidine (ac4C) modification, a conserved epitranscriptomic mark found in eukaryotic mRNAs and tRNAs. This acetylation plays a role in regulating RNA stability, translation efficiency, and cellular stress responses. NAT10's involvement in diverse biological processes, including cell proliferation, DNA damage repair, and nucleolar function, has made it a subject of interest in cancer, aging, and developmental studies.
NAT10-specific antibodies are critical tools for investigating its expression, localization, and molecular interactions. They are widely used in techniques like Western blotting, immunofluorescence, and immunoprecipitation to study NAT10's role in health and disease. Research has linked NAT10 dysregulation to tumor progression, metastasis, and chemoresistance in cancers, as well as age-associated pathologies. Antibodies targeting NAT10 have also facilitated the exploration of its crosstalk with other epigenetic regulators and its potential as a therapeutic target. Commercial NAT10 antibodies are typically developed against conserved regions (e.g., amino acid residues 600-850 in humans) and validated for species reactivity (human, mouse, rat) and application-specific performance. Recent studies emphasize the importance of NAT10 in RNA metabolism, positioning these antibodies as essential reagents for epitranscriptomics research.